Correvio collects and processes your personal data in accordance with the EU General Data Protection Regulation (GDPR).
By emailing firstname.lastname@example.org and/or submitting your personal information as requested in the Reporting form you consent to the processing of your personal data in accordance with our Privacy Statement. The collected information will be used only for the management of your request and will be stored for a limited period, proportionate to the aims pursued. If you have any questions or concerns about the collection and processing of your personal data, you can email your request to the following address: email@example.com.
In Phase 2/3 clinical studies, 2473 patients received Xydalba administered as either a single infusion of 1500 mg or as 1000 mg followed 1 week later by 500 mg.
The most common adverse reactions were generally mild or moderate in severity.
This medicinal product is subject to additional monitoring.